Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sohvi Hörkkö, David A. Bird, Elizabeth Miller, Hiroyuki Itabe, Norbert Leitinger, Ganesamoorthy Subbanagounder, Judith A. Berliner, Peter Friedman, Edward A. Dennis, Linda K. Curtiss, Wulf Palinski, Joseph L. Witztum
Published in Volume 103, Issue 1
J Clin Invest. 1999; 103(1):117–128 doi:10.1172/JCI4533
Abstract | Full text | PDF
Options: View larger image (or click on image)
Jci9904533
Figure 9

(a and b) Immunoassay showing binding of EO3, EO6, and F(ab′)2 fragments of EO3 and EO6 to CuOx-LDL. Increasing concentrations of antibodies or F(ab′)2 were incubated in CuOx-LDL–coated wells for 1 h at room temperature, and the amount of antibody bound was measured with alkaline phosphatase–labeled goat anti–mouse IgM antibody using chemiluminescent technique. (c) Binding of 2 μg (4 μg/ml) of 125I-CuOx-LDL to elicited mouse peritoneal macrophages in the presence or absence of 10 and 20 μg of unlabeled LDL, CuOx-LDL, monoclonal autoantibodies EO3 and EO6, and F(ab′)2 fragments of EO3 and EO6 as competitors. The data are expressed as the percentage of 125I-CuOx-LDL bound in the absence of competitors (0.6 μg/mg cell protein). Each value is the mean of triplicate determinations.